Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 272,800 shares, a decrease of 14.5% from the August 15th total of 318,900 shares. Based on an average daily volume of 2,700,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.3% of the company’s shares are sold short.
Adial Pharmaceuticals Stock Performance
NASDAQ:ADIL opened at $1.08 on Monday. Adial Pharmaceuticals has a 52 week low of $0.77 and a 52 week high of $4.30. The stock’s fifty day moving average is $1.04 and its two-hundred day moving average is $1.38.
Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.20). Equities research analysts predict that Adial Pharmaceuticals will post -1.62 EPS for the current fiscal year.
Institutional Trading of Adial Pharmaceuticals
Adial Pharmaceuticals Company Profile
Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
Featured Articles
- Five stocks we like better than Adial Pharmaceuticals
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- CD Calculator: Certificate of Deposit Calculator
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.